Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07205718RecruitingPhase 1/Phase 2
TAK-188 for advanced solid tumors after immunotherapy
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT06922500Recruiting
Brain-Wave Monitoring During Brain Tumor Surgery
This study tests a special brain-wave monitor (called processed EEG) during surgery to remove a brain tumor. The monitor helps the anesthesiologist keep you at the right level of sleep, which may improve safety and recovery.
LundAges 18 years+ - NCT07043751RecruitingPhase 1
TQB6411 for advanced solid tumors
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
Beijing, Beijing MunicipalityAges 18–75 - NCT07189949RecruitingPhase 1
Study of HRS-2329 for advanced solid tumors with RAS changes
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06234397RecruitingPhase 1
Study of BH3120 with or without pembrolizumab for advanced cancers
This trial tests a new drug, BH3120, alone or with pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the combination can help your immune system fight cancer more effectively.
Tampa, FloridaAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06710379RecruitingPhase 1
Testing ADRX-0405 for advanced solid tumors
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
Duarte, CaliforniaAges 18 years+ - NCT07087197RecruitingPhase 1
Study of SKB107 for advanced cancer with bone tumors
This trial tests a new drug, SKB107, for people whose advanced cancer has spread to the bones and standard treatments no longer work. The goal is to see if SKB107 can help shrink or slow these bone tumors.
ShanghaiAges 18–75 - NCT07338838RecruitingPhase 1
Testing TQB3142 in advanced tumors
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
Guangzhou, GuangdongAges 18–75 - NCT07100210RecruitingPhase 1
Study of a new drug for advanced solid tumors that haven't responded to treatment
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
Chengdu, SichuanAges 18–70 - NCT07561437RecruitingEarly Phase 1
NK521 infusion for advanced cancer with fluid buildup
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07561554RecruitingPhase 1
New BRAF-Targeting Drug for Advanced Solid Tumors
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05773937RecruitingPhase 1
Study drug for advanced solid tumors after prior treatments
This Phase 1 study tests 9MW2821 in people with advanced solid cancers that have grown despite earlier treatment. It aims to find the safest dose and learn how the drug works, and it may be an option if you can provide tumor tissue and meet key health criteria.
Beijing, Beijing MunicipalityAges 18–80 - NCT07327632RecruitingEarly Phase 1
Testing IBI3026 for advanced solid tumors
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
Chengdu, SichuanAges 18 years+ - NCT05205109RecruitingPhase 1
Testing a new melanoma drug alone and with pembrolizumab
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Sydney, New South WalesAges 18 years+ - NCT03736889RecruitingPhase 2
Tislelizumab for MSI-H or dMMR solid tumors after prior treatment
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
Hefei, AnhuiAges 18 years+ - NCT07321574RecruitingPhase 2
Testing ABP1011T for advanced solid tumors
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Luoyang, HenanAges 18–75 - NCT07185243Recruiting
Study of virus injection plus immunotherapy for advanced solid tumors
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Xiamen, FujianAges 18–75 - NCT07032298RecruitingPhase 1
Testing SSGJ-612 for advanced solid tumors with HER2
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Luoyang, HenanAges 18–75 - NCT05725291RecruitingPhase 1
Early study drug for advanced cancers after other treatments
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT07387068RecruitingPhase 1
Testing GEN1079 for advanced solid tumors
This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT07107633RecruitingPhase 2
Imaging test for cancer spread in the abdomen
This trial tests a special imaging injection to see if it can better detect cancer that has spread to the lining of the abdomen in people with stomach or bowel cancer. If you are scheduled for surgery to remove or explore the cancer, this scan might help your doctor plan the best treatment.
ShanghaiAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.